Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Ascletis Pharma (1672 HK): Placement Bleak; Commercialization To Take Time; Lack Formidable Pipeline

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ascletis-pharma-inc" target="_blank" data-smartkarma-citation="entities:27265:1" rel="noopener">Ascletis Pharma Inc (1672 HK)</a> is placing ~69M shares at the price of HK$12.18 per share. The placing shares represent ~7% of the total issued shares of the company.</li>
<li>The company intends to use net proceeds for preparation, groundwork and launch of global Phase 3 trials of small molecule oral GLP-1 receptor agonist ASC30 for the treatment of obesity.</li>
<li>Although Ascletis has some near-term catalysts (trial data readout), we do not expect the spectacular rally in the share price over the last one year to be replicated again.</li>
</ul>



Ascletis Pharma Inc (1672 HK) is placing ~69M shares at the price of HK$12.18 per share. The placing shares represent ~7% of the total issued shares of the company.
The company intends to use net proceeds for preparation, groundwork and launch of global Phase 3 trials of small molecule oral GLP-1 receptor agonist ASC30 for the treatment of obesity.
Although Ascletis has some near-term catalysts (trial data readout), we do not expect the spectacular rally in the share price over the last one year to be replicated again.


Ascletis Pharma (1672 HK): Pipeline Not Appealing Enough to Make the Placement Attractive